昊天國際建投(01341.HK)授出6547.6萬股獎勵股份
格隆匯6月29日丨昊天國際建投(01341.HK)公佈,於2020年6月29日,董事會議決向四名關連承授人(包括執行董事霍先生及公司附屬公司三名董事)授出6547.6萬股關連獎勵股份,相當於現有已發行股份約1.30%及因配發獎勵股份而擴大的已發行股份總數約1.28%,該等獎勵股份將根據特別授權予以發行。
於股份獎勵計劃有效期內授出的獎勵股份數目以於要約日期的已發行股份總數10%為限。於本公告日期,已根據股份獎勵計劃向若干非關連承授人授出2627.5萬股獎勵股份,有關獎勵股份未獲行使。公司將向聯交所上市委員會申請批准關連獎勵股份於聯交所上市及買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.